|
Fairway began its
business model by acquiring a breakthrough
technology (optoaccoustic imaging) with pivotal
cancer and cardiovascular applications that
originated from the M.D. Anderson Cancer Center.
Fairway applied for and received approximately $7.4
million in Federal NIH grants to support the
commercialization process. In May 2006, after
establishing a standalone company (Seno Medical
www.senomedical.com)
and recruiting a dedicated management team, Fairway
executed a 10-year exclusive design and development
agreement with Seno. As of January 2009, Seno has
successfully raised $9 million and is engaged in
raising an additional $15 million. Fairway currently
owns approximately 20% of Seno. Successful Fairway
team experience has validated Fairway’s business
model and inspired it to reproduce the success.
Since 2006, the following companies have been added
to Fairway portfolio and are in different stages of
development.
In 2007, Fairway
signed an exclusive manufacturing agreement with
Monebo Technologies (www.monebo.com).
In 2008, Fairway
added TraumaTec (brain cooling device
www.traumatec.com)
and Endothelix (vascular screening test
www.endothelix.com).
In 2009, through
an equity transfer merger with In3 Ventures,
ThermaRx (urinary hesitancy treatment
www.thermarx.com),
IC Therapeutics (ischemic conditioning therapy
www.ictherapeutics.com)
and CardioNexus (cardiovascular imaging
www.cardionexus.com ) have been added to Fairway Portfolio
Companies.
|
